Several trials examining radiotherapy in hodgkin lymphoma move to phase II

Data from the phase I HD7 through HD11 trials proves promising enough to move on to phase II, according to Paul Bröckelmann, MD. In an interview with Targeted Oncology, Bröckelmann discusses the HD7 through HD11 trials, which examine various forms of radiotherapy in patients with Hodgkin lymphoma, as well as the future of immunotherapy in the disease type.
Targeted Oncology